智飞生物：获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Zhifei Biological has received approval for clinical trials of its new mRNA vaccine for COVID-19, developed by its subsidiary Anhui Zhifei Longcom Biopharmaceutical [1] Group 2 - The vaccine, named HK.3-JN.1, is aimed at preventing diseases caused by new coronavirus infections [1] - The approval was granted by the National Medical Products Administration, with the notification number 2026LP00481 [1]